Hassoun-Kheir Nasreen, Buetti Niccolò, Jaques David, Olivier Valérie, Chraiti Marie-Noelle, Perez Monique, de Kraker Marlieke Ea, Jackson Holly, Schrenzel Jacques, Saudan Patrick, Harbarth Stephan
Infection Control Program, Faculty of Medicine, Geneva University Hospitals, WHO Collaborating Center, Geneva, Switzerland.
INSERM, IAME, Université Paris-Cité, Paris, France.
Antimicrob Resist Infect Control. 2025 Aug 20;14(1):100. doi: 10.1186/s13756-025-01620-8.
Hemodialysis-associated bloodstream infections (BSIs) represent a significant burden for patients. Understanding the trends in BSIs among hemodialysis patients is crucial for informing strategies to reduce their incidence and improve patient outcomes. This study aimed to evaluate secular trends, identify causative organisms, assess resistance patterns, and determine the sources of hemodialysis-associated BSIs at Geneva University Hospitals, where Staphylococcus aureus screening and decolonization of hemodialysis patients have been implemented since the year 2000.
A longitudinal cohort study was conducted using data from 2006 to 23. We included all patients receiving maintenance hemodialysis treatment at our institution. A hemodialysis-associated BSI was defined as BSI occurring during active hemodialysis treatment and diagnosed either during hospital admission or in outpatient hemodialysis unit. Outcomes included incidence rates of hemodialysis-associated BSIs, trends in causative pathogens, sources, and resistant organisms. Poisson regression was used to model trends over time of incidence rate ratios (IRR).
A total of 313 true BSI episodes were identified in 218 hemodialysis patients over 11,413 patient-hemodialysis months. The overall BSI incidence rate was 2.7 episodes per 100 patient-hemodialysis-months, with a consistent decrease over time. Compared to 2006-08, hemodialysis-associated BSI rates decreased by 16% in 2009-11 (IRR 0.84, 95% confidence interval [CI] 0.60-1.18), and by a maximum of 44% in 2021-23 (IRR 0.56, 95% CI 0.36-0.83). The decreasing trend was mainly due to reduced S. aureus BSIs, while Enterobacterales BSIs rates remained stable. Catheter-related BSIs accounted for 41.5% of infections (130/313), with marked reduction following 2014. BSIs caused by resistant bacteria were rare, with decreasing trends of methicillin-resistant S. aureus.
Hemodialysis-associated BSI rates significantly declined, driven largely by reductions in S. aureus BSIs and catheter-related infections. No replacement by Gram-negative BSI was observed. Prevention of hemodialysis-associated BSI is key for reducing infection burden among hemodialysis patients.
血液透析相关血流感染(BSIs)给患者带来了沉重负担。了解血液透析患者中BSIs的趋势对于制定降低其发生率和改善患者预后的策略至关重要。本研究旨在评估长期趋势、确定致病微生物、评估耐药模式,并确定日内瓦大学医院血液透析相关BSIs的来源,自2000年以来该医院已对血液透析患者实施了金黄色葡萄球菌筛查和去定植。
利用2006年至2023年的数据进行了一项纵向队列研究。我们纳入了在本机构接受维持性血液透析治疗的所有患者。血液透析相关BSI被定义为在进行血液透析治疗期间发生的BSI,且在住院期间或门诊血液透析单元被诊断。结果包括血液透析相关BSIs的发病率、致病病原体的趋势、来源和耐药微生物。采用泊松回归对发病率比(IRR)随时间的趋势进行建模。
在11413个患者-血液透析月期间,218名血液透析患者中共确定了313次真正的BSI发作。总体BSI发病率为每100个患者-血液透析月2.7次发作,且随时间持续下降。与2006 - 2008年相比,2009 - 2011年血液透析相关BSI率下降了16%(IRR 0.84,95%置信区间[CI] 0.60 - 1.18),2021 - 2023年最多下降了44%(IRR 0.56,95% CI 0.36 - 0.83)。下降趋势主要归因于金黄色葡萄球菌BSIs的减少,而肠杆菌科BSIs率保持稳定。导管相关BSIs占感染的41.5%(130/313),2014年后显著减少。由耐药菌引起的BSIs很少见,耐甲氧西林金黄色葡萄球菌呈下降趋势。
血液透析相关BSI率显著下降,主要是由于金黄色葡萄球菌BSIs和导管相关感染的减少。未观察到革兰氏阴性菌BSI的替代情况。预防血液透析相关BSI是减轻血液透析患者感染负担的关键。